Welcome to our dedicated page for Milestone Pharmaceuticals news (Ticker: MIST), a resource for investors and traders seeking the latest updates and insights on Milestone Pharmaceuticals stock.
Milestone Pharmaceuticals Inc. (MIST) is a clinical-stage biopharmaceutical company pioneering patient-administered therapies for cardiovascular emergencies. This page serves as the definitive source for verified news and press releases related to MIST's innovative arrhythmia treatments, including etripamil nasal spray for PSVT and AFib-RVR management.
Investors and medical professionals will find timely updates on clinical trial progress, regulatory milestones, and strategic partnerships. Our curated news collection provides essential insights into the company's scientific advancements while maintaining compliance with financial disclosure standards.
Key content categories include FDA submission updates, phase 3 trial results analysis, intellectual property developments, and executive leadership announcements. All materials are vetted for accuracy and relevance to support informed decision-making.
Bookmark this page for streamlined access to MIST's latest developments in rapid-onset cardiovascular therapies. Check regularly for updates on groundbreaking treatment models that combine medical innovation with patient empowerment.
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) announced participation at the 22nd Annual Needham Virtual Healthcare Conference on April 19, 2023, at 3:45 p.m. ET. The live presentation will be available via webcast on the company's website.
Milestone focuses on innovative cardiovascular medicines, with its lead product candidate, etripamil, having recently completed a Phase 3 clinical program for treating paroxysmal supraventricular tachycardia (PSVT). It is also in a Phase 2 trial for atrial fibrillation with rapid ventricular rate (AFib-RVR). The company operates in both Canada and the United States.
Milestone Pharmaceuticals (MIST) reported its financial results for Q4 and FY 2022, highlighting significant corporate developments. Following a strategic financing of $125 million in March 2023, the company expects sufficient cash resources to fund operations into mid-2025. A New Drug Application (NDA) for etripamil, aimed at treating paroxysmal supraventricular tachycardia (PSVT), is expected to be submitted in Q3 2023. The Phase 3 RAPID trial showed positive topline results, with 64.3% of patients converting to sinus rhythm with etripamil compared to 31.2% on placebo. However, the company's operating loss increased to $58.4 million in FY 2022 from $42.9 million in FY 2021.
Milestone Pharmaceuticals (Nasdaq: MIST) announced a strategic financing of $125 million with RTW Investments to bolster the development of its investigational drug etripamil for treating paroxysmal supraventricular tachycardia (PSVT). Funds, including $64.6 million in cash resources, are allocated to support operations until mid-2025, including a New Drug Application (NDA) submission planned for Q3 2023. Etripamil aims to empower patients to manage PSVT outside hospital settings. The investment comprises $50 million in convertible notes and $75 million in royalty financing, subject to FDA approval.
Milestone Pharmaceuticals has announced significant progress in the development of etripamil, an investigational treatment for paroxysmal supraventricular tachycardia (PSVT). The completion of NODE-303 and RAPID-extension studies paves the way for a New Drug Application (NDA) submission expected in Q3 2023, following positive feedback from the FDA. Etripamil aims to be the first fast-acting, patient-administered therapy for PSVT, potentially reducing reliance on emergency services. Recent Phase 3 trial results show 64.3% of patients converted to sinus rhythm within 30 minutes of self-administering etripamil, significantly higher than placebo (31.2%).
FAQ
What is the current stock price of Milestone Pharmaceuticals (MIST)?
What is the market cap of Milestone Pharmaceuticals (MIST)?
